Boryung on Monday launched Pomalikin capsules, the first generic version of pomalidomide in Korea, expanding treatment options for patients with multiple myeloma.

Pomalikin is available in four dosage strengths—1 mg, 2 mg, 3 mg, and 4 mg—and is the only generic in Korea with the same active ingredient, indication, administration route, and formulation as the original drug, Pomalyst, developed by Celgene, now part of Bristol Myers Squibb.

Pomalikin is approved for use in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy, including lenalidomide.

It is also indicated for use with dexamethasone in patients who have undergone at least two prior treatments, including both lenalidomide and bortezomib, and have relapsed or are refractory to treatment.

Boryung said Pomalikin has demonstrated bioequivalence to Pomalyst and is manufactured using high-quality ingredients sourced from suppliers registered with both Korea’s Ministry of Food and Drug Safety and the U.S. FDA’s drug master file (DMF) system.